Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DBV Technologies SA Sponsored ADR

Kintara Therapeutics

MEDNAX

Patterson Companies

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

ConocoPhillips

Cisco Systems

Hess

Humana

Paycom Software

Walgreens

Exxon Mobil

Energy was the sole S&P 500 sector to decline this month as the index marched toward its best month since July 2022.

These Stocks Were Left Behind In November's Historic Rally

U.S. health insurers Cigna and Humana are in talks to merge, a potential deal likely to face aggressive scrutiny from the U.S. Justice Department (DOJ) if antitrust history with similarly sized deals is any indication. The deal could exceed $60 billion in value.

Explainer: Why prior mega health insurer deals like the possible Cigna/Humana merger failed

Air Products and Chemicals

Becton, Dickinson and Co.

Dover

Johnson & Johnson

Mattel

This month, I've published two pieces about technical analysis — one on Bollinger Bands and another on the Relative Strength Indicator (RSI).

7 Blue-Chip Stocks to Buy for 2024, According to AI

UnitedHealth Group

The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.

Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles

A combination of the two health insurers will be scrutinized by the government, but that doesn't mean it won't have a good argument at court.

Cigna-Humana Merger Is Likely to Face Antitrust Challenge

News of a potential mega-merger between Cigna (CI) and Humana (HUM) made headlines in today's trading session and investors may be wondering if now is a good time to buy stock in these health giants.

Time to Buy Cigna (CI) or Humana's (HUM) Stock on News of a Potential Merger?

Humana and Cigna are reportedly in talks for a potential merger that could reshape the health insurance industry. A deal could be finalized by the end of the year, The Wall Street Journal (WSJ) reported Wednesday (Nov. 29), citing unnamed sources.

Report: Health Insurance Firms Humana and Cigna in Merger Talks

Shares of Cigna Group (CI) and Humana Inc. (HUM) plummeted during intraday trading Wednesday after a report that the huge health insurance companies could merge.

Cigna and Humana Shares Tumble After Report of Possible Merger

Are two leading health insurance providers about to merge? That question has been on investors' minds today as speculation mounts that Cigna (NYSE: CI ) and Humana (NYSE: HUM ) are on the verge of an important deal.

Health Insurance Stocks Cigna (CI), Humana (HUM) Eye Merger

Two of the biggest U.S. health insurers, Cigna and Humana , are in talks for what could be the largest merger announced this year, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

US health insurers Humana, Cigna in talks to merge -WSJ

Cigna Group (NYSE: CI) is trending down at writing following a report that it may soon merge with peer Humana Inc (NYSE: HUM). Cigna and Humana are discussing a potential merger Anonymous sources told the Wall Street Journal today that two of the largest U.S. health insurers are “in talks” over a stock-and-cash deal.

Cigna may soon merge with Humana: report

The Wall Street Journal says the two healthcare providers are talking about a stock-and-cash deal that could be finalized by the end of the year.

Cigna and Humana Are in Merger Talks, Report Says

Health insurers Cigna and Humana are in talks for a merger, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Health insurers Humana, Cigna in talks to merge - WSJ

Shares of Cigna fell on Wednesday after a report that the company is in talks with Humana about a merger between the two health care giants.

Cigna shares slide after report it could merge with Humana

Managed-care providers Cigna Group CI, -2.76% and Humana Inc. HUM, +0.17% are in talks to combine in a cash-and-stock deal that could be finalized before year-end, the Wall Street Journal reported Wednesday, citing people familiar with the matter. Cigna's market value stands at about $83 billion, while Humana's is about $62 billion, suggesting it would be mega deal.

Cigna and Humana in talks on combining in what would be a mega deal: WSJ

A cash-and-stock deal between the health-insurance giants could be struck by year-end.

Cigna, Humana in Talks for Blockbuster Merger

Cigna (CI) expects total medical customer growth to be a minimum of 1.4 million this year.

Here's Why Investors Should Hold Cigna (CI) Stock for Now

Centene

Molina Healthcare

Rising premiums, contract wins, a telehealth services suite and the M&A strategy are expected to drive the performances of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from encouraging industry prospects.

5 HMO Stocks Set to Gain From Growing Membership, Tech Advancements

Cigna's (CI) sub-unit Express Scripts introduces a pricing option for prescription drugs that may bolster the customer base and fetch higher pharmacy revenues to the health insurer.

Cigna (CI) Unit Unveils Pricing Model for Pharmacy Clients

Express Scripts ClearNetworkSM offers employers and health plans a new option for simple, "cost-plus" pharmacy pricing for brand, generic, and specialty medications. ST. LOUIS , Nov. 14, 2023 /PRNewswire/ -- Express Scripts, the pharmacy benefits management (PBM) business of Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today announced a new pharmacy network option, Express Scripts ClearNetworkSM, for its clients – including employers, government organizations, and health plans.

Express Scripts Introduces New Option To Give Clients Maximum Simplicity in Drug Pricing

Cigna Group is a leading health insurance and pharmacy benefits provider in the US, with a strong customer base and growth potential. The company's repositioning towards high-growth areas allows it to capitalize on emerging healthcare trends and support shareholder returns and business growth. CI's Evernorth segment, which includes pharmacy benefits management, is a significant driver of its net income and has the potential to generate additional revenue.

Cigna Delivering Growth At A Great Price

U.S. health insurer Cigna Group is exploring the sale of its Medicare Advantage business, which provides additional benefits to those covered by federal health insurance, a move that would mark a reversal of its expansion in the sector, according to people familiar with the matter.

Exclusive: Cigna explores shedding Medicare Advantage business -sources

Intel

Big cap stocks have resumed leadership. The NASDAQ and S&P 100 are likely to lead.

Stocks This Week: Buy Intel And Cigna

Automatic Data Processing

Albemarle

American Homes 4 Rent

Ares Capital

Alexandria Real Estate Equities

Bristol-Myers

British American Tobacco

Cincinnati Financial

Chevron

Deere & Company

Dollar General

Dick's Sporting Goods

EOG Resources

W.W. Grainger

Hershey

JPMorgan Chase & Co

KeyCorp

Lennar

Microchip Technology

MPLX

Microsoft

NextEra Energy

NXP Semiconductors

Old Dominion Freight Line

PepsiCo

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.

News for Cigna Stock (CI)